( convenientcombination products to pre...)Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years,Health

convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world - an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children with up to six diseases in one vaccine.

    Inquiries:


    US Media inquiries:              Liad Diamond            (919) 483 2839

                                     Nancy Pekarek           (919) 483 2839

                                     Mary Anne Rhyne         (919) 483 2839


    UK Media inquiries:              Philip Thomson          +44 20 8047 5502

                                     Joss Mathieson          +44 20 8047 5502

                                     Gwenan White            +44 20 8047 5502


    European Analyst/Investor        Anita Kidgell           +44 20 8047 5542

    inquiries:

                                     David Mawdsley          +44 20 8047 5564

                                     Sally Ferguson          +44 20 8047 5543


    US Analyst/ Investor inquiries:  Frank Murdolo           (215) 751 7002

                                     Tom Curry               (215) 751 5419

CONTACT: US Media, Liad Diamond, Nancy Pekarek or Mary Anne Rhyne,+1-919-483-2839, UK Media, Philip Thomson, Joss Mathieson or Gwenan White,+44-20-8047-5502, European Analyst-Investor inquiries, Anita Kidgell,+44-20-8047-5542, or David Mawdsley, +44-20-8047-5564, or Sally Ferguson,+44-20-8047-5543, or US Analyst-Investor inquiries, Frank Murdolo,+1-215-751-7002, or Tom Curry, +1-215-751-5419, all of GlaxoSmithKline

Web site: http://www.gsk.com/media/

Ticker Symbol: (NYSE:GSK)

Terms and conditions of use apply
Copyright © 2007 PR Ne
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
2. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
6. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell